2021 Nelson's Pediatric Antimicrobial Therapy

2021 Nelson's Pediatric Antimicrobial Therapy

by John S. Bradley

Paperback(27th ed.)

$36.95
Choose Expedited Shipping at checkout for delivery by Thursday, June 24

Overview

Completely updated and revised, the 27th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children, including COVID-19. For each disease, the authors provide a commentary to help select the best of all antimicrobial choices.

Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens.

New in the 27th edition:
  • Continuous updates of drug and dosing changes
  • 4 new chapters
  • Reorganized chapter order to improve functionality

Product Details

ISBN-13: 9781610024440
Publisher: American Academy of Pediatrics
Publication date: 01/01/2021
Edition description: 27th ed.
Pages: 362
Sales rank: 615,080
Product dimensions: 4.80(w) x 6.80(h) x 0.80(d)

About the Author

John S. Bradley, MD, FAAP has been the Director of the Division of Infectious Diseases at Rady Children's Hospital-San Diego since 1988, and is currently Professor and Chief, Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego School of Medicine. He has served on the American Academy of Pediatrics Committee on Infectious Diseases (Red Book Committee) 2004-2010, and the Council of the Pediatric Infectious Diseases Society (PIDS) Council, 2007-2011 where he promoted the development of a PIDS Antimicrobial Stewardship program.

John D. Nelson, MD is Professor Emeritus of Pediatrics at the University of Texas Southwestern Medical Center and Children's Medical Center, the same institution since he started his career back in 1957. At UT Southwestern he established the first formal Pediatric Infectious Disease fellowship program with Dr. Kenneth Haltalin and later Dr. George McCracken. He also went on to establish the National Pediatric Infectious Disease Seminar with Dr. McCracken and in 1982 they founded the Pediatric Infectious Disease Journal for which they continue as Chief Editors. In 1975 Dr. Nelson produced the first edition of the Pocket Book of Pediatric Antimicrobial Therapy which has gone through 20 biennial editions and is now edited by Dr. John Bradley. 

Elizabeth Barnett, MD, FAAP is Professor of Pediatrics at Boston University School of Medicine and Attending Physician at Boston Medical Center where she is Director of the Refugee Health Assessment Program and the International Clinic. Her clinical and research interests are general pediatric infectious diseases, immigrant and refugee medicine, travel medicine, and vaccines and vaccine safety. She is a Site Director for GeoSentinel (a global surveillance network for travel and migration associated health issues).

Joseph B. Cantey, MD, FAAP is an Assistant Professor of Pediatrics at the University of Texas Health San Antonio. He attended medical school at the Medical University of South Carolina before completing his pediatric residency at Johns Hopkins. He then completed dual fellowships in pediatric infectious diseases and neonatal/perinatal medicine at the University of Texas Southwestern in Dallas, Texas. His research interests include antimicrobial stewardship and responsible prescribing in the nursery setting; infection control and prevention in the nursery setting; and the pathogenesis, diagnosis, treatment, and longitudinal follow-up of congenital and perinatal infections, particularly herpes simplex virus, cytomegalovirus, and syphilis.

David W. Kimberlin, MD, FAAP is the Principal Investigator for the Collaborative Antiviral Study Group (CASG), an international network of pediatric academic medical centers that evaluates antiviral therapeutics in rare diseases with a large unmet medical need, including neonatal herpes simplex virus (HSV) infections, congenital cytomegalovirus (CMV) disease, congenital Zika infection, neonatal and infantile influenza infection, and neonatal enteroviral sepsis syndrome. Studies conducted by the CASG have led to new drug indications and label changes for acyclovir, valganciclovir, and oseltamivir, and non-CASG studies conducted by Dr. Kimberlin also have led to label changes for valacyclovir.
 
Dr. Kimberlin is Editor of the 2018-2021 AAP Report of the Committee on Infectious Diseases (Red Book). He also was Editor of the 2015 edition, and was an Associate Editor of the 2012 and 2009 editions. Dr. Kimberlin is a Past-President of the Pediatric Infectious Diseases Society (PIDS), which is the world's largest organization of professionals dedicated to the treatment, control, and eradication of infectious diseases affecting children. He also serves as Vice Chair for Clinical and Translational Research in the University of Alabama at Birmingham Department of Pediatrics, where he holds the Sergio Stagno Endowed Chair in Pediatric Infectious Diseases and is Co-Director of the Division of Pediatric Infectious Diseases.
 
Paul E. Palumbo, MD is a subspecialist in Pediatric Infectious Diseases at Dartmouth Medical School.  He specializes in pediatric HIV and TB disease.

Jason Sauberan, PharmD, is research pharmacist, study coordinator, and investigator at the Neonatal Research Institute, Sharp Mary Birch Hospital for Women and Newborns in San Diego, CA.  He also performs clinical duties as a neonatal intensive care pharmacist and antibiotic stewardship pharmacist for the Sharp Mary Birch 84-bed level III NICU, and as a pediatric consultant pharmacist at the Helen Bernardy Center for Medically Fragile Children, Rady Children’s Hospital San Diego.  His research interests include anti-infection therapy, drugs in breast milk, parenteral nutrition, and medication safety. He serves on the Scientific Advisory Board of Mother to Baby California, and is an assistant clinical professor, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences.

J. Howard Smart, MD, FAAP has been practicing General Pediatrics in San Diego since 1996, after completing his residency, which included working with Dr. Bradley at Children’s Hospital (now Rady’s). He is head of the Pediatrics department of his multi-specialty group and teaches in the UCSD residents’ clinic. His involvement with Nelson’s started with a conversation with Dr. Bradley while flying to an AAP conference, discussing his hobby of mobile app development. Dr. Smart has been an app developer since 2011, and brings together the two knowledge domains of computer science and pediatrics in creating the mobile version of Nelson’s.

William Steinbach, MD, FAAP is Professor of Pediatrics, Professor in Molecular Genetics and Microbiology, and Chief of Pediatric Infectious Diseases at Duke University. His expertise is in transplant infectious diseases, specifically in invasive fungal disease in children. He leads an integrated molecular, translational, and clinical research effort toward improving our understanding of invasive fungal disease epidemiology, diagnosis, and treatment.
 

Table of Contents

Introduction vii

Notable Changes to 2021 Nelson's Pediatric Antimicrobial Therapy, 27th Edition xi

1 Antimicrobial Therapy According to Clinical Syndromes 1

A Skin and Soft Tissue Infections 4

B Skeletal Infections 10

C Eye Infections 13

D Ear and Sinus Infections 17

E Oropharyngeal Infections 20

F Lower Respiratory Tract Infections 23

G Cardiovascular Infections 36

H Gastrointestinal Infections 44

I Genital and Sexually Transmitted Infections 50

J Central Nervous System Infections 55

K Urinary Tract Infections 60

L Miscellaneous Systemic Infections 62

2 Antimicrobial Therapy for Neonates 71

A Recommended Therapy for Selected Neonatal Conditions 74

B Antimicrobial Dosages for Neonates 95

C Aminoglycosides 99

D Vancomycin 100

E Use of Antimicrobials During Pregnancy or Breastfeeding 100

3 Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens 103

A Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Gram Positive) 104

B Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Gram Negative) 106

C Common Bacterial Pathogens and-Usual Pattern of Susceptibility to Antibiotics (Anaerobes) 108

D Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens 110

4 Choosing Among Antibiotics Within a Class: Beta-lactams and Beta-lactamase Inhibitors, Macrolides, Aminoglycosides, and Fluoroquinolones 131

5 Preferred Therapy for Specific Fungal Pathogens 139

A Overview of More Common Fungal Pathogens and Their Usual Pattern of Antifungal Susceptibilities 140

B Systemic Infections 142

C Localized Mucocutaneous Infections 156

6 Choosing Among Antifungal Agents: Polyenes, Azoles, and Echinocandins 159

7 Preferred Therapy for Specific Viral Pathogens 169

A Overview of Non-HIV, Non-Hepatitis B or C Viral Pathogens and Usual Pattern of Susceptibility to Antivirals 170

B Overview of Hepatitis B or C Viral Pathogens and Usual Pattern of Susceptibility to Antivirals 171

C Preferred Therapy for Specific Viral Pathogens 172

8 Choosing Among Antiviral Agents 187

9 Preferred Therapy for Specific Parasitic Pathogens 191

A Selected Common Pathogenic Parasites and Suggested Agents for Treatment 192

B Preferred Therapy for Specific Parasitic Pathogens 194

10 Choosing Among Antiparasitic Agents: Antimalarial Drugs, Nitroimidazoles, Benzimidazoles, and Neglected Tropical Diseases 217

11 How Antibiotic Dosages Are Determined Using Susceptibility Data, Pharmacodynamics, and Treatment Outcomes 219

12 Approach to Antibiotic Therapy of Drug-Resistant Gram-negative Bacilli and Methicillin-Resistant Staphylococcus aureus 223

13 Antibiotic Therapy for Children Who Are Obese 231

14 Sequential Parenteral-Oral Antibiotic Therapy (Oral Step-down Therapy) for Serious Infections 235

15 Antimicrobial Prophylaxis/Prevention of Symptomatic Infection 237

A Postexposure Antimicrobial Prophylaxis to Prevent Infection 239

B Long-term Antimicrobial Prophylaxis to Prevent Symptomatic New Infection 245

C Prophylaxis of Symptomatic Disease in Children Who Have Asymptomatic Infection/Latent Infection 247

D Surgical/Procedure Prophylaxis 248

16 Approach to Antibiotic Allergies 253

17 Antibiotic Stewardship 263

18 Alphabetic Listing of Antimicrobials 269

A Systemic Antimicrobials With Dosage Forms and Usual Dosages 271

B Topical Antimicrobials (Skin, Eye, Ear, Mucosa) 295

Appendix: Nomogram for Determining Body Surface Area 303

References 305

Index 331

Customer Reviews